QR Pharma, Inc.
QR Pharma, Inc. is listed today as Annovis Bio, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2023 | $1 M | Private placement after listing | Under $2 million | equity | SEC | |
| May 2015 | $1 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
QR Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2023).
SEC Form D · Apr 2023
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Apr 2023
That is all the official record says: QR Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of QR Pharma, Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Claudine Bruck | Person | not stated | not stated | Held Series A-1 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Maria-Luisa Maccecchini | Person | not stated | not stated | Held Series A and A-1 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Mark K. White | Person | not stated | not stated | Held Series A and A-1 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Michael B. Hoffman | Person | not stated | not stated | Held Series A and A-1 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Robert M. Whelan Jr. | Person | not stated | not stated | Held Series A-1 preferred stock, director (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 21 investors.
Largest shareholders today
Institutions holding Annovis Bio, Inc. shares, as of Sep 30, 2026.
- Marshall Wace, LLP$2 M3.99%
- Vanguard Capital Management LLC$2 M3.71%
- Two Sigma Investments, LP$1 M1.76%
- Renaissance Technologies LLC$1 M1.73%
- Geode Capital Management, LLC$0 M0.76%
- BlackRock, Inc.$0 M0.58%
- Susquehanna International Group, LLP$0 M0.57%
- Vanguard Fiduciary Trust Co$0 M0.53%
- Gsa Capital Partners LLP$0 M0.51%
- Citadel Advisors LLC$0 M0.50%
- Morgan Stanley$0 M0.47%
- UBS Group AG$0 M0.27%
- Greenwich Wealth Management LLC$0 M0.26%
- State Street Corp$0 M0.25%
- Northern Trust Corp$0 M0.16%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Henry Hagopian | Chief Financial Officer | Apr 2023 |
| Maria Maccecchini | Chief Executive Officer | Apr 2023 |
| Claudine Bruck | Director | Apr 2023 |
| Maria Maccecchini | Chief Executive Officer | Apr 2023 |
| Mark White | Director | Apr 2023 |
| Michael Hoffman | Director | Apr 2023 |
| Reid McCarthy | Director | Apr 2023 |
| Dhesh F. Govender | Director | Jun 2015 |
| Franz F. Hefti | Director | Jun 2015 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.